Arvinas, Inc. (NASDAQ:ARVN - Get Free Report)'s stock price was up 8.6% during trading on Wednesday . The stock traded as high as $8.13 and last traded at $8.12. Approximately 1,043,234 shares traded hands during mid-day trading, a decline of 52% from the average daily volume of 2,169,998 shares. The stock had previously closed at $7.48.
Analyst Ratings Changes
A number of brokerages have issued reports on ARVN. HC Wainwright set a $24.00 target price on shares of Arvinas in a research note on Monday, June 2nd. Barclays lowered their target price on shares of Arvinas from $32.00 to $16.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. The Goldman Sachs Group lowered their price objective on shares of Arvinas from $12.00 to $8.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. BMO Capital Markets lowered their price objective on shares of Arvinas from $20.00 to $10.00 and set an "outperform" rating for the company in a research report on Monday, May 5th. Finally, TD Cowen cut shares of Arvinas from a "buy" rating to a "hold" rating in a research note on Friday, May 2nd. Ten analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $20.29.
Read Our Latest Research Report on Arvinas
Arvinas Stock Performance
The company has a market cap of $541.59 million, a PE ratio of -11.24 and a beta of 2.22. The firm has a fifty day simple moving average of $7.55 and a 200 day simple moving average of $10.30.
Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $1.14 EPS for the quarter, topping the consensus estimate of ($0.93) by $2.07. Arvinas had a negative return on equity of 7.74% and a negative net margin of 10.92%. The firm's quarterly revenue was up 646.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.97) EPS. As a group, equities analysts predict that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.
Insider Buying and Selling
In related news, CFO Andrew Saik sold 5,700 shares of the firm's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $7.61, for a total transaction of $43,377.00. Following the completion of the transaction, the chief financial officer owned 164,401 shares of the company's stock, valued at $1,251,091.61. This trade represents a 3.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.73% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in ARVN. Vanguard Group Inc. lifted its position in shares of Arvinas by 18.4% during the 1st quarter. Vanguard Group Inc. now owns 8,362,200 shares of the company's stock worth $58,703,000 after buying an additional 1,299,639 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in Arvinas by 6.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,103,011 shares of the company's stock worth $78,656,000 after acquiring an additional 249,295 shares in the last quarter. RTW Investments LP raised its holdings in Arvinas by 19.8% during the fourth quarter. RTW Investments LP now owns 3,334,308 shares of the company's stock worth $63,919,000 after acquiring an additional 551,979 shares in the last quarter. T. Rowe Price Investment Management Inc. acquired a new position in shares of Arvinas in the fourth quarter valued at approximately $42,332,000. Finally, Alyeska Investment Group L.P. acquired a new position in shares of Arvinas in the first quarter valued at approximately $12,636,000. Institutional investors and hedge funds own 95.19% of the company's stock.
Arvinas Company Profile
(
Get Free Report)
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Featured Stories
Before you consider Arvinas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arvinas wasn't on the list.
While Arvinas currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access